Clinical trials: Fibrosis Myocardial
Heart Failure
A Study Of The Usage Of Statins In A Community Heart Failure Population
Inflammation and fibrosis may be important contributors to worsening heart failure. As well as lowering cholesterol, statins are also known to reduce inflammatory markers such as C-reactive protein which are elevated in severe…
- Trial name
- NCT00795912
- Testing
- Atorvastatin
- Where
- Ireland
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- St Vincent's University Hospital, Ireland
ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus
Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction
The DAPA-STEMI trial investigates whether dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), reduces heart muscle scarring (fibrosis) and improves heart function after a ST-segment elevation myocardial infarction…
- Conditions
- ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus, Heart Failure, Myocardial Fibrosis
- Trial name
- DAPA-STEMI (NCT06619600)
- Testing
- Dapagliflozin
- Where
- 2 sites in Spain
- Volunteers
- 54 people
- Sponsor
- Hospital Clinic of Barcelona
Heart Failure
Risk Stratification Via HF-QRS and Fibrosis Biomarkers in Heart Failure
This study aims to evaluate whether high-frequency QRS (HF-QRS) signal parameters and circulating myocardial fibrosis biomarkers (such as PIIINP, Galectin-3, and sST2) can improve risk stratification in patients with chronic…
- Trial name
- STRIVE (NCT06959186)
- Volunteers
- 1,500 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Myocardial Fibrosis, Muscular Dystrophies
Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial
This trial intends to evaluate myocardial Fibrosis progression in Duchenne and Becker Muscular Dystrophy, as well the influence of ACE inhibitors in fibrosis progression.
- Trial name
- NCT02432885
- Testing
- Enalapril
- Volunteers
- 76 people
- Sponsor
- InCor Heart Institute
Hypertrophic Cardiomyopathy
Pirfenidone to Treat Hypertrophic Cardiomyopathy
This study will examine the effectiveness of the drug pirfenidone (Deskar) in improving heart function in patients with hypertrophic cardiomyopathy (HCM).
- Trial name
- NCT00011076
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Ventricular Tachycardia, Monomorphic, Ventricular Tachycardia (V-Tach)
Imaging and Treatment Planning for Cardiac Radioablation
Cardiac radioablation is a new treatment for ventricular tachycardia (VT), which uses beams of radiation to treat heart scar that causes VT.
- Conditions
- Ventricular Tachycardia, Monomorphic, Ventricular Tachycardia (V-Tach), Ischemia, Myocardial
- Trial name
- ITPCR (NCT06938074)
- Testing
- CT and MRI
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Stewart Gaede
Cirrhosis, Cardiomyopathy
Subclinical Myocardial Dysfunction in Patients With Hepatic Cirrhosis
The prevalence of hepatic cirrhosis in Romania is very high, with a 10-year mortality of 34-66%. Upward trend of mortality is observed. It is known that cirrhosis is associated with cardiac abnormalities.
- Trial name
- CIRRHECHO (NCT01713478)
- Testing
- echocardiography
- Where
- Romania
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Carol Davila University of Medicine and Pharmacy
Myocardial Fibrosis
Validation of Fibrosis Quantification Using T1 Mapping Against Histology as Reference and Comparison With Fibrosis Biomarkers
Myocardial fibrosis is recognized as the pathologic entity of extracellular matrix remodeling. Diffuse, reactive fibrosis is increasingly recognized in a variety of conditions despite the absence of ischemia.
- Trial name
- NCT02834104
- Testing
- RMI, myocardial biopsy, blood sample
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Acute Myocardial Infarction, Coronary Artery Disease
Cardiac MRI for Patients Enrolled in INFUSE-AMI
Background: INFUSE AMI is an ongoing clinical trial examining how patients with heart attacks are treated. The study's aim is to help determine the best way to treat patients with specific kinds of heart attacks caused by blood…
- Conditions
- Acute Myocardial Infarction, Coronary Artery Disease, Myocardial Fibrosis, Gadolinium
- Trial name
- NCT01059214
- Where
- United States
- Volunteers
- 455 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Obesity, Type 2 Diabetes
The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics
This is a prospective, randomized, open-label, active drug controlled clinical trial that aims to compare the effects of henagliflozin or metformin on myocardial tissue level characteristics in type 2 diabetes patients with…
- Conditions
- Obesity, Type 2 Diabetes, Sodium-glucose Co-transporter-2 Inhibitor, Myocardial Fibrosis
- Trial name
- NCT06059287
- Testing
- Henagliflozin, Metformin
- Volunteers
- 64 people
- Sponsor
- RenJi Hospital
Aortic Stenosis, Calcific
Prognostic Value of Myocardial Fibrosis in Severe Aortic Valve Stenosis
Degenerative aortic valve stenosis (AS) is the most common valve heart disease in the developed Western countries. The hemodynamic progression of AS occurs over time and leads to LV hypertrophy (LVH) as a compensation mechanism…
- Trial name
- FIB-AS (NCT03585933)
- Testing
- Cardiac magnetic resonance imaging
- Where
- 2 sites in Denmark, Lithuania
- Volunteers
- 110 people
- Sponsor
- Vilnius University
Patient Participation, Heart Defects, Congenital
Liver Disease, Myocardial Fibrosis and Collaterals in the Adult Fontan Patient a Metabolomics and Proteomics Approach
Out objective is to identify the mechanisms that promote hepatic and myocardial fibrosis, and collateral vessel formation in patients with complex congenital heart disease and Fontan circulation.
- Conditions
- Patient Participation, Heart Defects, Congenital, Liver Diseases, Collateral Circulation, Any Site
- Trial name
- NCT04764305
- Where
- Austria
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
Arrhythmogenic Right Ventricular Cardiomyopathy, FAPI PET
FAPI PET/CT Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) (FAPI-ARVC))
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease associated with fibrofatty myocardial replacement, ventricular arrhythmias, and an increased risk of sudden cardiac death.
- Conditions
- Arrhythmogenic Right Ventricular Cardiomyopathy, FAPI PET, Cardiac Magnetic Resonance Imaging
- Trial name
- FAPI-ARVC (NCT07563660)
- Testing
- 68Ga-DOTA-SA-FAPI PET/CT
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- Istanbul University - Cerrahpasa
Myocardial Fibrosis, Left Ventricle Hypertrophy
A Health Coach-Led Digital Lifestyle Intervention (HEALDI)
Aim: To evaluate the effectiveness of an artificial intelligence (AI)-assisted 12-month Health Coach-Led Digital Lifestyle Intervention (HEALDI) versus control on diffuse myocardial fibrosis and ambulatory blood pressure in…
- Conditions
- Myocardial Fibrosis, Left Ventricle Hypertrophy, Hypertensive Disease, Hypertension
- Trial name
- NCT07530562
- Testing
- HEALDI Intervention
- Volunteers
- 200 people
- Sponsor
- National University of Singapore
Acute Myocardial Infarction (AMI)
the Relationship Between FAPI Results and Myocardial Fibrosis After Acute Myocardial Infarction
FAPI is a new method to discover the fibrosis of cardiac myocardium in some conditions, like myocardial infarction or cardiomyopathy.
- Trial name
- NCT06841549
- Testing
- FAPI
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
HFpEF
Predictors of Poor Prognosis in HFpEF
Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.
- Trial name
- NCT06844032
- Where
- Russia
- Volunteers
- 500 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Fibrosis Myocardial
Effects of Interval Training Effects on Cardiac Fibrosis
The study aimed to highlight the effect of high-intensity interval training (HIIT) on cardiac fibrosis in cardiac patients. From 2009-2018, cardiac patients with measurements of VO2peak, b-type natriuretic peptide, quality of…
- Trial name
- NCT04038723
- Testing
- High-intensity interval training
- Volunteers
- 12 people
- Sponsor
- Chang Gung Memorial Hospital
Myocardial Infarction, Myocardial Fibrosis
PROFILE-MI - The FAPI Fibrosis Study
The investigators here propose to investigate the timing and pattern of myocardial fibrosis activity following acute myocardial infarction using hybrid 68Ga-FAPI positron emission tomography and cardiovascular magnetic resonance.
- Trial name
- NCT05356923
- Testing
- 68Gallium FAPI PET/MR scan
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Heart Failure
Effect of Genetic Polymorphism on the Clinical Outcome of Patients With Heart Failure
Heart failure (HF) is one the most common cause of hospitalization and represents the end stage of a variety of heart conditions; it is associated with significant morbidity and mortality.The pathophysiology of HF is centered on…
- Trial name
- SNPs (NCT03122834)
- Where
- Egypt
- Volunteers
- 246 people
- Sponsor
- Ain Shams University
Cardiomyopathy, Coronary Artery Disease
The Prognostic Significance of Fibrosis Detection in Cardiomyopathy
The presence of scar within heart muscle can act as a substrate for abnormal rhythm problems and lead to the developement of heart failure Clinical significance Correlation with biomarkers and genetic markers
- Trial name
- NCT00930735
- Where
- United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust